Nasdaq · CIK 0001764013
IMVT Immunovant, Inc.
Insider trading from SEC Form 4. Last filing 4 d ago. Close $30.47 on Oct 9, 2026, +79% from the 52-week low and -32% from the high.
Immunovant, Inc. (IMVT) has 77 SEC Form 4 filings on file from 14 insiders, the latest filed on Oct 9, 2026. In the last 90 days insiders made 0 open-market buys worth $0 and 5 open-market sells worth $460k, net -$460k.
58 open-market trades have been scored at IMVT. The newest: Melanie Gloria (Chief Operating Officer) sold $72k of stock on Oct 7, 2026, filed Oct 9, 2026, scored 43 (moderate). The largest of the 50 shown: Roivant Sciences Ltd. (director and 10% owner) bought $350M on Dec 12, 2025, scored 43 (moderate). 4 insiders sold within 14 days of each other around Oct 7, 2026.
IMVT closed at $30.47 on Oct 9, 2026, 79% above its 52-week low and 32% below its 52-week high.
10 Form 144 notices of planned sales are on file, the latest filed Jun 25, 2025.
Last 90 days
Net insider value
-$460k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
5
$460k by 4 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
IMVTOct 9, 2026 · close 30.47
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Immunovant, Inc., scored: the newest 50 of 58.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Melanie Gloria Chief Operating Officer sell | $72k 2,241 shares | -1% | +99% from low-29% from high | |
| 40Moderate | Jay S Stout Chief Technology Officer sell | $122k 3,809 shares | -2% | +99% from low-29% from high | |
| 36Weak | Christopher Van Tuyl Chief Legal Officer sell | $43k 1,327 shares | -1% | +99% from low-29% from high | |
| 35Weak | Eric Venker Chief Executive Officer sell | $120k 3,506 shares | -1% | +109% from low-25% from high | |
| 40Moderate | Christopher Van Tuyl Chief Legal Officer sell | $103k 2,846 shares | -2% | +132% from low-23% from high | |
| 45Moderate | Andrew J. Fromkin director sell | $7.4M 221,951 shares | -75% | +138% from low-6% from high | |
| 23Weak | Christopher Van Tuyl Chief Legal Officer sell | $72k 2,877 shares | -2% | +77% from low-15% from high | |
| 29Weak | Melanie Gloria Chief Operating Officer sell | $90k 3,238 shares | -2% | +105% from low-1% from high | |
| 22Weak | Jay S Stout Chief Technology Officer sell | $51k 1,977 shares | -1% | +95% from low-6% from high | |
| 20Weak | Jay S Stout Chief Technology Officer sell | $32k 1,203 shares | -1% | +101% from low-3% from high | |
| 29Weak | Christopher Van Tuyl Chief Legal Officer sell | $291k 10,813 shares | -7% | +97% from low-3% from high | |
| 43Moderate | Roivant Sciences Ltd. director, owner buy | $350M 16,666,666 shares | +17% | +99% from low-5% from high | |
| 33Weak | Andrew J. Fromkin director sell | $517k 22,249 shares | -21% | +71% from low-21% from high | |
| 30Weak | Douglas J. Hughes director sell | $349k 15,000 shares | -11% | +71% from low-21% from high | |
| 49Moderate | Melanie Gloria Chief Operating Officer sell | $298k 12,626 shares | -7% | +71% from low-21% from high | |
| 30Weak | Michael Geffner Chief Medical Officer sell | $49k 2,595 shares | -1% | +42% from low-40% from high | |
| 30Weak | Jay S Stout Chief Technology Officer sell | $48k 2,520 shares | -1% | +42% from low-40% from high | |
| 23Weak | Michael Geffner Chief Medical Officer sell | $21k 1,272 shares | -1% | +21% from low-49% from high | |
| 28Weak | Jay S Stout Chief Technology Officer sell | $26k 1,585 shares | -1% | +21% from low-49% from high | |
| 29Weak | Michael Geffner Chief Medical Officer sell | $43k 2,385 shares | -1% | +38% from low-41% from high | |
| 30Weak | Jay S Stout Chief Technology Officer sell | $51k 2,805 shares | -1% | +38% from low-41% from high | |
| 23Weak | Michael Geffner Chief Medical Officer sell | $20k 1,160 shares | -1% | +30% from low-45% from high | |
| 28Weak | Jay S Stout Chief Technology Officer sell | $26k 1,519 shares | -1% | +30% from low-45% from high | |
| 36Weak | Michael Geffner Chief Medical Officer sell | $35k 2,349 shares | -1% | +9% from low-54% from high | |
| 35Weak | Jay S Stout Chief Technology Officer sell | $28k 1,925 shares | -1% | +9% from low-54% from high | |
| 43Moderate | Eva Renee Barnett Chief Financial Officer sell | $45k 2,993 shares | -1% | +12% from low-53% from high | |
| 50Moderate | Peter Salzmann Chief Executive Officer sell | $124k 8,321 shares | -1% | +12% from low-53% from high | |
| 48Moderate | Eva Renee Barnett Chief Financial Officer sell | $144k 11,063 shares | -3% | +12% from low-53% from high | |
| 39Weak | Michael Geffner Chief Medical Officer sell | $80k 6,169 shares | -3% | +12% from low-53% from high | |
| 55Moderate | Peter Salzmann Chief Executive Officer sell | $365k 28,094 shares | -2% | +12% from low-53% from high | |
| 38Weak | Jay S Stout Chief Technology Officer sell | $65k 5,004 shares | -2% | +12% from low-53% from high | |
| 6Weak | Andrew J. Fromkin director sell | $157k 8,000 shares | -8% | - | |
| 44Moderate | Eva Renee Barnett Chief Financial Officer sell | $59k 2,814 shares | -1% | - | |
| 54Moderate | Peter Salzmann Chief Executive Officer sell | $322k 15,439 shares | -2% | - | |
| 36Weak | William L. Macias Chief Medical Officer sell | $43k 2,055 shares | -1% | - | |
| 38Weak | Michael Geffner Chief Medical Officer sell | $63k 2,657 shares | -2% | - | |
| 37Weak | Jay S Stout Chief Technology Officer sell | $52k 2,195 shares | -2% | - | |
| 44Moderate | Eva Renee Barnett Chief Financial Officer sell | $55k 2,298 shares | -1% | - | |
| 52Moderate | Peter Salzmann Chief Executive Officer sell | $209k 8,767 shares | -1% | - | |
| 37Weak | William L. Macias Chief Medical Officer sell | $57k 2,383 shares | -1% | - | |
| 46Moderate | Roivant Sciences Ltd. director, owner buy | $337M 16,845,010 shares | +21% | - | |
| 47Moderate | Eva Renee Barnett Chief Financial Officer sell | $99k 4,105 shares | -1% | - | |
| 50Moderate | Peter Salzmann Chief Executive Officer sell | $123k 5,105 shares | -1% | - | |
| 21Weak | Douglas J. Hughes director sell | $155k 5,425 shares | -4% | - | |
| 22Weak | Atul Pande director sell | $221k 7,750 shares | -8% | - | |
| 47Moderate | Eva Renee Barnett Chief Financial Officer sell | $106k 4,174 shares | -1% | - | |
| 56Moderate | Peter Salzmann Chief Executive Officer sell | $425k 16,692 shares | -2% | - | |
| 39Weak | William L. Macias Chief Medical Officer sell | $85k 3,353 shares | -1% | - | |
| 40Moderate | Mark S. Levine Chief Legal Officer sell | $93k 3,650 shares | -1% | - | |
| 40Moderate | Michael Geffner Chief Medical Officer sell | $94k 3,189 shares | -2% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 25, 2025 | WILLIAM MACIAS Officer | 30,000 0.02% of outstanding | $475k | Jun 25, 2025 | $2.2M |
| Jun 13, 2025 | WILLIAM MACIAS Officer | 50,000 0.03% of outstanding | $778k | Jun 13, 2025 | $1.4M |
| Jun 3, 2025 | WILLIAM MACIAS Officer | 80,000 0.05% of outstanding | $1.2M | Jun 3, 2025 | $189k |
| May 21, 2025 | GEORGE V MIGAUSKY Former Director | 21,812 0.01% of outstanding | $318k | May 21, 2025 | $411k |
| May 19, 2025 | GEORGE V MIGAUSKY Former Director | 28,188 0.02% of outstanding | $411k | May 19, 2025 | none |
| Mar 7, 2025 | ANDREW J FROMKIN Director | 8,000 0.00% of outstanding | $156k | Mar 7, 2025 | none |
| Feb 14, 2025 | MARK S LEVINE Former Affiliate | 69,763 0.04% of outstanding | $1.4M | Feb 14, 2025 | $663k |
| Feb 11, 2025 | MARK S LEVINE Former Affiliate | 29,196 0.02% of outstanding | $570k | Feb 11, 2025 | $93k |
| Dec 2, 2024 | DOUGLAS J. HUGHES Officer | 5,425 0.00% of outstanding | $153k | Dec 2, 2024 | none |
| Dec 2, 2024 | ATUL CHANDRA PANDE Director | 7,750 0.01% of outstanding | $219k | Dec 2, 2024 | none |
Transactions
The newest 50 of 125 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -2,213 | $32.06 | $71k | 203,128 | 4 d ago |
| Oct 7, 2026 | Christopher Van Tuyl Chief Legal Officer | SOpen-market sale Common Stock | -1,327 | $32.06 | $43k | 175,218 | 4 d ago |
| Oct 7, 2026 | Melanie Gloria Chief Operating Officer | SOpen-market sale Common Stock | -2,241 | $32.06 | $72k | 217,060 | 4 d ago |
| Oct 7, 2026 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -1,596 | $32.06 | $51k | 201,532 | 4 d ago |
| Oct 1, 2026 | Eric Venker Chief Executive Officer | MOption exercise Common Stock | +92,187 | $14.46 | $1.3M | 346,467 | 8 d ago |
| Oct 1, 2026 | Eric Venker Chief Executive Officer | DDisposition to issuer Common Stock | -85,886 | $33.65 | $2.9M | 260,581 | 8 d ago |
| Oct 2, 2026 | Eric Venker Chief Executive Officer | SOpen-market sale Common Stock | -3,506 | $34.11 | $120k | 257,075 | 8 d ago |
| Oct 1, 2026 | Eric Venker Chief Executive Officer | MOption exercise Capped Value Appreciation Rightsderivative | -92,187 | $0.00 | $0 | 921,875 | 8 d ago |
| Sep 23, 2026 | Christopher Van Tuyl Chief Legal Officer | SOpen-market sale Common Stock | -2,846 | $36.36 | $103k | 176,545 | 18 d ago |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Common Stock | +31,668 | $4.99 | $158k | 131,400 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Common Stock | +71,492 | $7.94 | $568k | 202,892 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Common Stock | +77,181 | $8.43 | $651k | 280,073 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Common Stock | +16,260 | $14.70 | $239k | 296,333 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | SOpen-market sale Common Stock | -11,483 | $32.64 | $375k | 284,850 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | SOpen-market sale Common Stock | -210,468 | $33.56 | $7.1M | 74,382 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Stock Option (right to buy)derivative | -31,668 | $0.00 | $0 | 0 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Stock Option (right to buy)derivative | -71,492 | $0.00 | $0 | 0 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Stock Option (right to buy)derivative | -77,181 | $0.00 | $0 | 0 | May 29, 2026 |
| May 28, 2026 | Andrew J. Fromkin director | MOption exercise Stock Option (right to buy)derivative | -16,260 | $0.00 | $0 | 0 | May 29, 2026 |
| Apr 7, 2026 | Jake Bauer director | AGrant or award Common Stock | +13,880 | $0.00 | $0 | 38,896 | Apr 9, 2026 |
| Apr 7, 2026 | Andrew J. Fromkin director | AGrant or award Common Stock | +13,880 | $0.00 | $0 | 99,732 | Apr 9, 2026 |
| Apr 7, 2026 | Jake Bauer director | AGrant or award Stock Option (right to buy)derivative | +7,061 | $0.00 | $0 | 7,061 | Apr 9, 2026 |
| Apr 7, 2026 | Andrew J. Fromkin director | AGrant or award Stock Option (right to buy)derivative | +7,061 | $0.00 | $0 | 7,061 | Apr 9, 2026 |
| Mar 18, 2026 | Christopher Van Tuyl Chief Legal Officer | SOpen-market sale Common Stock | -2,877 | $24.97 | $72k | 147,053 | Mar 20, 2026 |
| Feb 25, 2026 | Melanie Gloria Chief Operating Officer | SOpen-market sale Common Stock | -1,437 | $26.98 | $39k | 172,074 | Feb 27, 2026 |
| Feb 25, 2026 | Melanie Gloria Chief Operating Officer | SOpen-market sale Common Stock | -859 | $28.16 | $24k | 171,215 | Feb 27, 2026 |
| Feb 25, 2026 | Melanie Gloria Chief Operating Officer | SOpen-market sale Common Stock | -942 | $28.90 | $27k | 170,273 | Feb 27, 2026 |
| Jan 21, 2026 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -1,977 | $26.03 | $51k | 197,634 | Jan 23, 2026 |
| Jan 7, 2026 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -1,148 | $26.51 | $30k | 199,666 | Jan 9, 2026 |
| Jan 7, 2026 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -55 | $26.92 | $1,481 | 199,611 | Jan 9, 2026 |
| Dec 18, 2025 | Christopher Van Tuyl Chief Legal Officer | SOpen-market sale Common Stock | -8,529 | $26.78 | $228k | 152,214 | Dec 19, 2025 |
| Dec 18, 2025 | Christopher Van Tuyl Chief Legal Officer | SOpen-market sale Common Stock | -2,284 | $27.38 | $63k | 149,930 | Dec 19, 2025 |
| Dec 12, 2025 | Roivant Sciences Ltd. director, owner | POpen-market purchase Common Stock, $0.0001 par value per share | +16,666,666 | $21.00 | $350M | 113,317,007 | Dec 12, 2025 |
| Dec 1, 2025 | Andrew J. Fromkin director | SOpen-market sale Common Stock10b5-1 | -19,351 | $23.14 | $448k | 88,750 | Dec 3, 2025 |
| Dec 1, 2025 | Douglas J. Hughes director | SOpen-market sale Common Stock10b5-1 | -13,091 | $23.14 | $303k | 122,682 | Dec 3, 2025 |
| Dec 1, 2025 | Andrew J. Fromkin director | SOpen-market sale Common Stock10b5-1 | -2,898 | $23.95 | $69k | 85,852 | Dec 3, 2025 |
| Dec 1, 2025 | Douglas J. Hughes director | SOpen-market sale Common Stock10b5-1 | -1,909 | $23.96 | $46k | 120,773 | Dec 3, 2025 |
| Nov 20, 2025 | Melanie Gloria Chief Operating Officer | SOpen-market sale Common Stock | -10,251 | $23.54 | $241k | 175,886 | Nov 21, 2025 |
| Nov 20, 2025 | Melanie Gloria Chief Operating Officer | SOpen-market sale Common Stock | -2,375 | $23.97 | $57k | 173,511 | Nov 21, 2025 |
| Oct 22, 2025 | Michael Geffner Chief Medical Officer | SOpen-market sale Common Stock | -2,595 | $19.03 | $49k | 217,958 | Oct 24, 2025 |
| Oct 22, 2025 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -2,520 | $19.03 | $48k | 200,814 | Oct 24, 2025 |
| Oct 8, 2025 | Michael Geffner Chief Medical Officer | SOpen-market sale Common Stock | -1,272 | $16.30 | $21k | 220,553 | Oct 10, 2025 |
| Oct 8, 2025 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -1,585 | $16.30 | $26k | 203,334 | Oct 10, 2025 |
| Jul 28, 2025 | Eric Venker Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +1,300,000 | $0.00 | $0 | 1,300,000 | Jul 30, 2025 |
| Jul 28, 2025 | Eric Venker Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +189,900 | $0.00 | $0 | 189,900 | Jul 30, 2025 |
| Jul 28, 2025 | Eric Venker Chief Executive Officer | AGrant or award Capped Value Appreciation Rightsderivative | +1,475,000 | $0.00 | $0 | 1,475,000 | Jul 30, 2025 |
| Jul 23, 2025 | Michael Geffner Chief Medical Officer | SOpen-market sale Common Stock | -2,385 | $18.15 | $43k | 221,825 | Jul 25, 2025 |
| Jul 23, 2025 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -2,805 | $18.15 | $51k | 204,919 | Jul 25, 2025 |
| Jul 9, 2025 | Michael Geffner Chief Medical Officer | SOpen-market sale Common Stock | -1,160 | $17.24 | $20k | 224,210 | Jul 11, 2025 |
| Jul 9, 2025 | Jay S Stout Chief Technology Officer | SOpen-market sale Common Stock | -1,519 | $17.24 | $26k | 207,724 | Jul 11, 2025 |
50 of 125 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Eva Renee BarnettChief Financial Officer
- Jake Bauerdirector
- Andrew J. Fromkindirector
- Michael GeffnerChief Medical Officer
- Melanie GloriaChief Operating Officer
- Douglas J. Hughesdirector
- Mark S. LevineChief Legal Officer
- William L. MaciasChief Medical Officer
- Atul Pandedirector
- Roivant Sciences Ltd.director, owner
- Peter SalzmannChief Executive Officer
- Jay S StoutChief Technology Officer
- Christopher Van TuylChief Legal Officer
- Eric VenkerChief Executive Officer
Questions about IMVT
Answered from the filings on this page, as of the latest one.
Are insiders buying IMVT?
As of Oct 9, 2026, SEC Form 4 filings show 0 open-market buys worth $0 by 0 insiders and 5 open-market sells worth $460k by 4 insiders at Immunovant, Inc. in the last 90 days, net -$460k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade IMVT on the open market?
Melanie Gloria (Chief Operating Officer) sold $72k of IMVT on Oct 7, 2026 and filed the Form 4 on Oct 9, 2026. InsiderTell scored 43 (moderate), with 4 insiders on the same side within 14 days.
How many insiders file Form 4 at Immunovant, Inc.?
14 people have filed a Form 4 at Immunovant, Inc., among them Eva Renee Barnett (Chief Financial Officer), Jake Bauer (director), Andrew J. Fromkin (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.